The U.S. Supreme Court has temporarily blocked a lower court ruling that would have severely limited mail access to mifepristone, the medication used in medication abortion. Justice Samuel Alito issued the pause on Tuesday, keeping the current FDA regulations in place through at least Thursday while the Court considers the case further.
The federal appeals court had sided with anti-abortion groups seeking to reverse FDA approvals that allow mifepristone to be dispensed by mail and prescribed via telehealth. Those approvals, originally granted in 2000 and expanded in 2023, enable patients to obtain the medication without in-person clinic visits. The appeals court ruling would have required patients to pick up mifepristone in person from a pharmacy or clinic.
This temporary measure buys time as the Supreme Court weighs a broader challenge to mifepristone's FDA approval. The case centers on whether plaintiffs have legal standing to challenge the drug's approval and whether the FDA's regulatory decisions overstepped its authority.
Medication abortion accounts for more than half of all U.S. abortions. Access by mail has become particularly important in states that have restricted or banned surgical abortion since the Supreme Court overturned Roe v. Wade in 2022. Many patients in restrictive states depend on mail delivery from providers in states where abortion remains legal.
The temporary pause preserves access during a period of legal uncertainty. Any permanent ruling by the Supreme Court could reshape how and where patients nationwide can obtain mifepristone. The Court's decision carries stakes for reproductive freedom and healthcare delivery in an increasingly fragmented legal landscape where abortion access varies dramatically by state.